The orexins/hypocretins and schizophrenia

Schizophrenia Bulletin

Volumn 33, Issue 6, 2007, Pages 1277-1283

  Deutch, Ariel Y ^a,b   Bubser, Michael ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Psychiatric Hospital at Vanderbilt   (United States)

Author keywords

Antipsychotic drugs; Cognition; Dopamine

Indexed keywords

AMPHETAMINE; CLOZAPINE; HALOPERIDOL; MODAFINIL; NEUROLEPTIC AGENT; OLANZAPINE; OREXIN; OREXIN 1 RECEPTOR; OREXIN 2 RECEPTOR; OREXIN A; OREXIN ANTAGONIST; OREXIN B; PLACEBO; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ATTENTION; BRAIN CORTEX; BRAIN NERVE CELL; BRAIN REGION; CATALEPSY; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; DOPAMINERGIC NERVE CELL; DRUG ACTIVITY; DRUG MECHANISM; HUMAN; NARCOLEPSY; NEUROANATOMY; NONHUMAN; PEPTIDE ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN ISOLATION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; REVIEW; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; WEIGHT GAIN;

BENZHYDRYL COMPOUNDS; BRAIN; CENTRAL NERVOUS SYSTEM STIMULANTS; CHROMOSOMES, HUMAN, PAIR 17; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NEUROPEPTIDES; SCHIZOPHRENIA;

EID: 35648985743     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbm096     Document Type: Review

References (81)

1. de Lecea L, Kilduff TS, Peyron C, et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci USA. 1998;95:322-327.
2. Sakurai T, Amemiya A, Ishii M, et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell. 1998;92:573-585.
3. Lin L, Faraco J, Li R, et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell. 1999;98:365-376.
4. Chemelli RM, Willie JT, Sinton CM, et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell. 1999;98:437-451.
5. Nishino S, Ripley B, Overeem S, Lammers GJ, Mignot E. Hypocretin (orexin) deficiency in human narcolepsy. Lancet. 2000;355:39-40.
6. Winsky-Sommerer R, Boutrel B, De Lecea L. The role of the hypocretinergic system in the integration of networks that dictate the states of arousal. Drug News Perspect. 2003;16:504-512.
7. Berridge CW, Espana RA. Hypocretins: waking, arousal, or action? Neuron. 2005;46:696-698.
8. Jones BE. From waking to sleeping: neuronal and chemical substrates. Trends Pharmacol Sci. 2005;26:578-586.
9. Spinazzi R, Andreis PG, Rossi GP, Nussdorfer GG. Orexins in the regulation of the hypothalamic-pituitary-adrenal axis. Pharmacol Rev. 2006;58:46-57.
10. Zeitzer JM, Nishino S, Mignot E. The neurobiology of hypocretins (orexins), narcolepsy and related therapeutic interventions. Trends Pharmacol Sci. 2006;27:368-374.
11. Carr D, Kalivas PW. Orexin: a gatekeeper of addiction. Nat Med. 2006;2:274-276.
12. Saper CB. Staying awake for dinner: hypothalamic integration of sleep, feeding, and circadian rhythms. Prog Brain Res. 2006;153:243-252.
13. Harris GC, Aston-Jones G. Arousal and reward: a dichotomy in orexin function. Trends Neurosci. 2006;29:571-577.
14. Siegel JM, Boehmer LN. Narcolepsy and the hypocretin system-where motion meets emotion. Nat Clin Pract Neurol. 2006;2:548-556.
15. Bingham MJ, Cai J, Deehan MR. Eating, sleeping and rewarding: orexin receptors and their antagonists. Curr Opin Drug Discov Devel. 2006;9:551-559.
16. Scammell TE, Saper CB. Orexins: looking forward to sleep, back at addiction. Nat Med. 2007;13:126-128.
17. Sakurai T. The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness. Nat Rev Neurosci. 2007;8:171-181.
18. Sakurai T, Moriguchi T, Furuya K, et al. Structure and function of human prepro-orexin gene. J Biol Chem. 1999;274:17771-17776.
19. Zhu Y, Miwa Y, Yamanaka A. Orexin receptor type-1 couples exclusively to pertussis toxin-insensitive G-proteins, while orexin receptor type-2 couples to both pertussis toxinsensitive and -insensitive G-proteins. J Pharmacol Sci. 2003;92:259-266.
20. Thannickal TC, Moore RY, Nienhuis R, et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron. 2000;27:469-474.
21. Sutcliffe JG, de Lecea L. The hypocretins: setting the arousal threshold. Nat Rev Neurosci. 2002;3:339-349.
22. España RA, Reis KM, Valentino RJ, Berridge CW. Organization of hypocretin/orexin efferents to locus coeruleus and basal forebrain arousal-related structures. J Comp Neurol. 2005;481:160-178.
23. Peyron C, Tighe DK, van den Pol AN, et al. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci. 1998;18:9996-10015.
24. Hervieu GJ, Cluderay JE, Harrison DC, Roberts JC, Leslie RA. Gene expression and protein distribution of the orexin-1 receptor in the rat brain and spinal cord. Neuroscience. 2001;103:777-797.
25. Trivedi P, Yu H, MacNeil DJ, Van der Ploeg LH, Guan XM. Distribution of orexin receptor mRNA in the rat brain. FEBS Lett. 1998;438:71-75.
26. Cluderay JE, Harrison DC, Hervieu GJ. Protein distribution of the orexin-2 receptor in the rat central nervous system. Regul Pept. 2002;104:131-144.
27. Fadel J, Deutch AY. Anatomical substrates of orexindopamine interactions: lateral hypothalamic projections to the ventral tegmental area. Neuroscience. 2002;111:379-387.
28. Nakamura T, Uramura K, Nambu T, et al. Orexin-induced hyperlocomotion and stereotypy are mediated by the dopaminergic system. Brain Res. 2000;873:181-187.
29. Uramura K, Funahashi H, Muroya S, Shioda S, Takigawa M, Yada T. Orexin-a activates phospholipase C- and protein kinase C-mediated Ca2+ signaling in dopamine neurons of the ventral tegmental area. Neuroreport. 2001;12:1885-1889.
30. Balcita-Pedicino JJ, Sesack SR. Orexin axons in the rat ventral tegmental area synapse infrequently onto dopamine and gamma-aminobutyric acid neurons. J Comp Neurol. 2007;503:668-684.
31. Fuxe K, Dahlstrom A, Hoistad M, et al. From the Golgi-Cajal mapping to the transmitter-based characterization of the neuronal networks leading to two modes of brain communication: Wiring and volume transmission. Brain Res Rev. 2007. doi: 10.1016/jbrainresrev.2007.02.009.
32. Berendse HW, Groenewegen HJ. Restricted cortical termination fields of the midline and intralaminar thalamic nuclei in the rat. Neuroscience. 1991;42:73-102.
33. Bubser M, Deutch AY. Thalamic paraventricular nucleus neurons collateralize to innervate the prefrontal cortex and nucleus accumbens. Brain Res. 1998;787:304-310.
34. Huang H, Ghosh P, van den Pol AN. Prefrontal cortexprojecting glutamatergic thalamic paraventricular nucleusexcited by hypocretin: a feedforward circuit that may enhance cognitive arousal. J Neurophysiol. 2006;95:1656-1668.
35. Leibowitz SF, Brown LL. Histochemical and pharmacological analysis of catecholaminergic projections to the perifornical hypothalamus in relation to feeding inhibition. Brain Res. 1980;201:315-345.
36. Deutch AY, Fadel J, Bubser M. Dopamine - hypocretin/orexin interactions: The prefrontal cortex and schizophrenia. In: de Lecea L, Sutcliffe JG, eds. Hypocretins-Integrators of Physiological Functions. New York, NY: Springer; 2005:337-349.
37. Lu J, Jhou TC, Saper CB. Identification of wake-active dopaminergic neurons in the ventral periaqueductal gray matter. J Neurosci. 2006;26:193-202.
38. Yoshida K, McCormack S, España RA, Crocker A, Scammel TE. Afferents to the orexin neurons of the rat brain. J Comp Neurol. 2006;94:845-861.
39. Bubser M, Fadel JR, Jackson LL, Meador-Woodruff JH, Jing D, Deutch AY. Dopaminergic regulation of orexin neurons. Eur J Neurosci. 2005;21:2993-3001.
40. Eriksson KS, Sergeeva O, Brown RE, Haas HL. Orexin/ hypocretin excites the histaminergic neurons of the tuberomammillary nucleus. J Neurosci. 2001;21:9273-9279.
41. Baldo BA, Daniel RA, Berridge CW, Kelley AE. Overlapping distributions of orexin/hypocretin- and dopamine-beta-hydroxylase immunoreactive fibers in rat brain regionsmediating arousal, motivation, and stress. J Comp Neurol. 2003;464:220-237.
42. Henny P, Jones BE. Innervation of orexin/hypocretin neurons by GABAergic, glutamatergic or cholinergic basal forebrain terminals evidenced by immunostaining for presynaptic vesicular transporter and postsynaptic scaffolding proteins. J Comp Neurol. 2006;499:645-661.
43. Scammell TE. The neurobiology, diagnosis, and treatment of narcolepsy Ann Neurol. 2003;53:154-166.
44. Siegel JM. Hypocretin (orexin): role in normal behavior and neuropathology. Annu Rev Psychol. 2004;55:125-148.
45. Benson KL. Sleep in schizophrenia: impairments, correlates, and treatment. Psychiatr Clin North Am. 2006;29:1033-1045.
46. Lin JS, Hou Y, Jouvet M. Potential brain neuronal targets for amphetamine-, methylphenidate-, and modafinil-induced wakefulness, evidenced by c-fos immuno-cytochemistry in the cat. Proc Natl Acad Sci USA. 1995;93:14128-14133.
47. Scammell TE, Estabrooke IV, McCarthy MT, et al. Hypothalamic arousal regions are activated during modafinil-induced wakefulness. J Neurosci. 2000;20:8620-8628.
48. Teitelman E. Modafinil for narcolepsy. Am J Psychiatry. 2001;158:970-971.
49. Makela EH, Miller K, Cutlip WD2nd. Three case reports of modafinil use in treating sedation induced by antipsychotic medications. J Clin Psychiatry. 2003;64:485-486.
50. DeQuardo JR. Modafinil and antipsychotic-induced sedation. J Clin Psychiatry. 2004;65:278-279.
51. Douglass AB, Hays P, Pazderka F, Russell JM. Florid refractory schizophrenias that turn out to be treatable variants of HLA-associated narcolepsy. J Nerv Ment Dis. 1991;179:12-17; discussion 18.
52. Douglass AB, Shipley JE, Haines RF, Scholten RC, Dudley E, Tapp A. Schizophrenia, narcolepsy, and HLA-DR15, DQ6. Biol Psychiatry. 1993;34:773-780.
53. Bhat SK, Galang R. Narcolepsy presenting as schizophrenia. Am J Psychiatry. 2002;159:1245.
54. Kishi Y, Konishi S, Koizumi S, Kudo Y, Kurosawa H, Kathol RG. Schizophrenia and narcolepsy: a review with a case report. Psychiatry Clin Neurosci. 2004;58:117-124.
55. Walterfang M, Upjohn E, Velakoulis D. Is schizophrenia associated with narcolepsy? Cogn Behav Neurol. 2005;18:113-118.
56. Kondziella D, Arlien-Soborg P. Diagnostic and therapeutic challenges in narcolepsy-related psychosis. J Clin Psychiatry. 2006;67:1817-1819.
57. Nishino S, Ripley B, Mignot E, Benson KL, Zarcone VP. CSF hypocretin-1 levels in schizophrenics and controls: relationship to sleep architecture. Psychiatry Res. 2002;110:1-7.
58. Schulz H, Wilde-Frenz J. Symposium: cognitive processes and sleep disturbances: The disturbance of cognitive processes in narcolepsy. J Sleep Res. 1995;4:10-14.
59. Fulda S, Schulz H. Cognitive dysfunction in sleep disorders. Sleep Med Rev. 2001;5:423-445.
60. Naumann A, Daum I. Narcolepsy: pathophysiology and neuropsychological changes. Behav Neurol. 2003;14:89-98.
61. Naumann A, Bierbrauer J, Przuntek H, Daum I. Attentive and preattentive processing in narcolepsy as revealed by eventrelated potentials (ERPs). Neuroreport. 2001;12:2807-2811.
62. Rieger M, Mayer G, Gauggel S. Attention deficits in patients with narcolepsy. Sleep. 2003;26:36-43.
63. Randall DC, Shneerson JM, Plaha KK, File SE. Modafinil affects mood, but not cognitive function, in healthy young volunteers. Hum Psychopharmacol. 2003;18:163-73.
64. Turner DC, Robbins TW, Clark L, Aron AR, Dowson J, Sahakian BJ. Cognitive enhancing effects of modafinil in healthy volunteers. Psychopharmacology (Berl). 2003;165:260-269.
65. Rosenthal MH, Bryant SL. Benefits of adjunct modafinil in an open-label, pilot study in patients with schizophrenia. Clin Neuropharmacol. 2004;27:38-43.
66. Hunter MD, Ganesan V, Wilkinson ID, Spence SA. Impact of modafinil on prefrontal executive function in schizophrenia. Am J Psychiatry. 2006;163:2184-2186.
67. Turner DC, Clark L, Pomarol-Clotet E, McKenna P, Robbins TW, Sahakian BJ. Modafinil improves cognition and attentional set shifting in patients with chronic schizophrenia. Neuropsychopharmacology. 2004;29:1363-1373.
68. Sevy S, Rosenthal MH, Alvir J, et al. Double-blind, placebocontrolled study of modafinil for fatigue and cognition in schizophrenia patients treated with psychotropic medications. J Clin Psychiatry. 2005;66:839-843.
69. Pierre JM, Peloian JH, Wirshing DA, Wirshing WC, Marder SR. A randomized, double-blind, placebo-controlled trial of modafinil for negative symptoms in schizophrenia. J Clin Psychiatry. 2007;68:705-710.
70. Spence SA, Green RD, Wilkinson ID, Hunter MD. Modafinil modulates anterior cingulate function in chronic schizophrenia. Br J Psychiatry. 2005;187:55-61.
71. Fadel J, Bubser M, Deutch AY. Differential activation of orexin neurons by antipsychotic drugs associated with weight gain. J. Neurosci. 2002;22:6742-6746.
72. Meltzer HY, Perry E, Jayathilake K. Clozapine-induced weight gain predicts improvement in psychopathology. Schiz Res. 2002;59:19-27.
73. Ascher-Svanum H, Stensland MD, Kinon BJ, Tollefson GD. Weight gain as a prognostic indicator of therapeutic improvement during acute treatment of schizophrenia with placebo or active antipsychotic. J Psychopharmacol. 2005;19(Suppl):110-117.
74. Kinon BJ, Kaiser CJ, Ahmed S, Rotelli MD, Kollack-Walker S. Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders. J Clin Psychopharmacol. 2005;25:255-258.
75. Vittoz NM, Berridge CW. Hypocretin/orexin selectively increases dopamine efflux within the prefrontal cortex: involvement of the ventral tegmental area. Neuropsychopharmacology. 2006;31:384-395.
76. Dalal MA, Schuld A, Pollmacher T. Lower CSF orexin A (hypocretin-1) levels in patients with schizophrenia treated with haloperidol compared to unmedicated subjects. Mol Psychiatry. 2003;8:836-837.
77. Glantz LA, Lewis DA. Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia. Arch Gen Psychiatry. 2000;57:65-73.
78. Wang H-D, Deutch AY. Dopamine depletion of the prefrontal cortex induces dendritic spine loss: reversal by atypical antipsychotic drug treatment. Neuropsychopharmacology. 2007. doi: 10.1038/sj.npp.1301521.
79. Mignot E, Nishino S, Guilleminault C, Dement WC. Modafinil binds to the dopamine uptake carrier site with low affinity. Sleep. 1994;17:436-437.
80. Keefe RS, Bilder RM, Davis SM, et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry. 2007;64:633-647.
81. Glick ID, Pham D, Davis JM. Concomitant medications may not improve outcome of antipsychotic monotherapy for stabilized patients with nonacute schizophrenia. J Clin Psychiatry. 2006;67:1261-1265.